The rumored $400 billion merger discussions between AstraZeneca and Bristol Myers Squibb didn’t get very far, but the episode offered another indication of the strategic pressure facing large pharmaceutical companies as they confront patent expirations and an increasingly demanding commercial environment.

The question for pharma leaders is no longer simply how to reduce costs or replace lost revenue. It is whether they have the capabilities, evidence and organizational discipline to compete in the market that is emerging.